Skip to main content

Images are character representations of Demodex mites.

illustrated demodex mites holding party favors

Treat the Eyelid Mite Party: Discover the XDEMVY® Effect

Images are character representations of Demodex mites.

Illustrated demodex mite peers around a bottle of XDEMVY next to party favors in a puddle of liquid

One drop per eye, twice a day (~12 hours apart), for 6 weeks.

XDEMVY Targets and Kills the Mites  That Cause Demodex Blepharitis (DB)

XDEMVY was created specifically to treat Demodex blepharitis

XDEMVY is the first and only FDA-approved treatment for DB.1,2

Illustrated demodex mite peers around a bottle of XDEMVY next to party favors in a puddle of liquid

One drop per eye, twice a day (~12 hours apart), for 6 weeks.

  • One drop per eye, twice a day, approximately 12 hours apart, in just six weeks

    In two combined studies, 50% of patients had a reduction of crusties (collarettes) and  60% of patients had their Demodex mites completely wiped out.3*

    Before XDEMVY

    eyelid afflicted with demodex blepharitis db

    After XDEMVY

    eyelid cured of demodex blepharitis db

    Images are of actual patient who participated in clinical trials for Tarsus Pharmaceuticals. Results may vary.
    Patient with DB used XDEMVY twice daily, in each eye for 6 weeks.

  • Designed for patient comfort

    ~90% of patients in both trials reported XDEMVY eye drops as neutral to very comfortable to use.3†

  • Stay on top of your treatment

    It’s important to use XDEMVY for the full six weeks.

  • Reduce eyelid redness

    Patients using XDEMVY for DB may see eyelid redness gone in just 6 weeks.1,2

XDEMVY for Demodex blepharitis was evaluated in 2 pivotal trials of 833 patients (415 received XDEMVY).2,4,5 Trial 1: When taken twice daily in each eye for 6 weeks, compared to those who did not receive XDEMVY, XDEMVY reduced collarettes to 2 or less for the upper eyelid in 44% of patients (N=209) at Day 43; 
XDEMVY eradicated mites (mite density of 0 mites/lash) in 68% of patients (N=212) at Day 43. Trial 2: When taken twice daily in each eye for 6 weeks, compared to those who did not receive XDEMVY,XDEMVY reduced collarettes to 2 or less for the upper eyelid in 55% of patients (N=193) at Day 43; XDEMVY eradicated mites (mite density of 0 mites/lash) in 50% of patients (N=203) at Day 43.2

All visits averaged.3

illustrated demodex mite saying no way is paralyzed along with text that reads party’s over
References

References: 1. Data on File. XDEMVY Pivotal Trial Data Presentation. Tarsus Pharmaceuticals, Inc. 2. XDEMVY. Prescribing Information. Tarsus Pharmaceuticals, Inc; 2023. 3. Yeu E, Vollmer P, et al. Treatment of Demodex blepharitis with lotilaner ophthalmic solution (0.25%): combined analysis of two pivotal randomized, vehicle-controlled, multicenter trials. and Saturn-2 combined data. Presented at: ARVO 2023; April 25-27, 2023; New Orleans, LA. 4. Gaddie IB, Donnenfeld ED, Karpecki P, et al. Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2) [published online ahead of print, 2023 Jun 5]. Ophthalmology. 2023;S0161-6420(23)00392-5. 5. Yeu E, Wirta DL, Karpecki P, Baba SN, Holdbrook M; Saturn I Study Group. Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1). Cornea. 2023;42(4):435-443.

References: 1. Data on File. XDEMVY Pivotal Trial Data Presentation. Tarsus Pharmaceuticals, Inc. 2. XDEMVY. Prescribing Information. Tarsus Pharmaceuticals, Inc; 2023. 3. Yeu E, Vollmer P, et al. Treatment of Demodex blepharitis with lotilaner ophthalmic solution (0.25%): combined analysis of two pivotal randomized, vehicle-controlled, multicenter trials. and Saturn-2 combined data. Presented at: ARVO 2023; April 25-27, 2023; New Orleans, LA. 4. Gaddie IB, Donnenfeld ED, Karpecki P, et al. Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2) [published online ahead of print, 2023 Jun 5]. Ophthalmology. 2023;S0161-6420(23)00392-5. 5. Yeu E, Wirta DL, Karpecki P, Baba SN, Holdbrook M; Saturn I Study Group. Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1). Cornea. 2023;42(4):435-443.